热门资讯> 正文

哈罗公学子公司ImprimisRx任命新首席执行官

2025-10-06 19:44

Harrow (NASDAQ:HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx; Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx.
Mr. Mullery is a senior executive with over 20 years of leadership experience in the healthcare and pharmaceutical industries.

More on Harrow Health

Harrow, Inc. (HROW) Analyst/Investor Day Transcript
Harrow: Buy A Blend Of Value And Growth
Harrow: A Classical GARP Stock
Harrow to buy Melt Pharmaceuticals
Harrow launches $250M debt offering

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。